The 36-month beta value for BCRX is at 1.89. Analysts have varying views on the stock, with 5 analysts rating it as a “buy,” 2 rating it as “overweight,” 2 as “hold,” and 1 as “sell.”
The public float for BCRX is 198.09M, and currently, shorts hold a 9.03% of that float. The average trading volume for BCRX on July 24, 2024 was 3.64M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
BCRX) stock’s latest price update
The stock of Biocryst Pharmaceuticals Inc. (NASDAQ: BCRX) has increased by 0.67 when compared to last closing price of 7.42. Despite this, the company has experienced a -2.10% fall in its stock price over the last five trading sessions. globenewswire.com reported 2024-07-22 that RESEARCH TRIANGLE PARK, N.C., July 22, 2024 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its second quarter 2024 financial results on Monday, August 5, 2024.
BCRX’s Market Performance
BCRX’s stock has fallen by -2.10% in the past week, with a monthly rise of 16.36% and a quarterly rise of 69.39%. The volatility ratio for the week is 4.42% while the volatility levels for the last 30 days are 4.44% for Biocryst Pharmaceuticals Inc. The simple moving average for the last 20 days is 11.29% for BCRX stock, with a simple moving average of 30.37% for the last 200 days.
Analysts’ Opinion of BCRX
Many brokerage firms have already submitted their reports for BCRX stocks, with JP Morgan repeating the rating for BCRX by listing it as a “Overweight.” The predicted price for BCRX in the upcoming period, according to JP Morgan is $10 based on the research report published on November 20, 2023 of the previous year 2023.
RBC Capital Mkts, on the other hand, stated in their research note that they expect to see BCRX reach a price target of $10, previously predicting the price at $9. The rating they have provided for BCRX stocks is “Outperform” according to the report published on September 18th, 2023.
Jefferies gave a rating of “Buy” to BCRX, setting the target price at $11 in the report published on August 04th of the previous year.
BCRX Trading at 16.13% from the 50-Day Moving Average
After a stumble in the market that brought BCRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -6.04% of loss for the given period.
Volatility was left at 4.44%, however, over the last 30 days, the volatility rate increased by 4.42%, as shares surge +19.14% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +39.89% upper at present.
During the last 5 trading sessions, BCRX fell by -2.10%, which changed the moving average for the period of 200-days by +19.52% in comparison to the 20-day moving average, which settled at $6.77. In addition, Biocryst Pharmaceuticals Inc. saw 24.71% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BCRX starting from McKee Amy E, who sale 8,600 shares at the price of $6.32 back on Jun 24 ’24. After this action, McKee Amy E now owns 27,831 shares of Biocryst Pharmaceuticals Inc., valued at $54,352 using the latest closing price.
SANDERS MACHELLE, the Director of Biocryst Pharmaceuticals Inc., sale 4,689 shares at $6.00 during a trade that took place back on Jun 17 ’24, which means that SANDERS MACHELLE is holding 27,742 shares at $28,134 based on the most recent closing price.
Stock Fundamentals for BCRX
Current profitability levels for the company are sitting at:
- -0.25 for the present operating margin
- 0.98 for the gross margin
The net margin for Biocryst Pharmaceuticals Inc. stands at -0.59. The total capital return value is set at -0.26.
Based on Biocryst Pharmaceuticals Inc. (BCRX), the company’s capital structure generated 2.36 points at debt to capital in total, while cash flow to debt ratio is standing at -0.12. The debt to equity ratio resting at -1.74. The interest coverage ratio of the stock is -0.85.
Currently, EBITDA for the company is -102.05 million with net debt to EBITDA at -9.63. When we switch over and look at the enterprise to sales, we see a ratio of 6.43. The receivables turnover for the company is 5.87for trailing twelve months and the total asset turnover is 0.76. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.73.
Conclusion
In conclusion, Biocryst Pharmaceuticals Inc. (BCRX) has had a better performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
